Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6586476 | 0.89 | HTR2A (0.42) | HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL6594865 | 0.87 | PDGFRA (0.40) | SIGMAR1MEN1CYP3A4CYP2D6KMT2A | |
| SCHEMBL6590059 | 0.79 | DDB1 (0.33) | KMT2A | |
| SCHEMBL6587917 | 0.78 | SIGMAR1 (0.34) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL1388099 | 0.76 | SIGMAR1 (0.55) | SIGMAR1HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL6250927 | 0.73 | ADRA1A (0.54) | SIGMAR1MEN1CYP2D6KMT2A | |
| SCHEMBL6590715 | 0.71 | HTR2A (0.37) | HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL769063 | 0.70 | ADRA1A (0.55) | MEN1CYP2D6KMT2A | |
| SCHEMBL6589223 | 0.69 | PDGFRA (0.35) | MEN1CYP3A4CYP2D6KMT2A | |
| SCHEMBL6589282 | 0.69 | HTR2A (0.40) | HTR2AHTR2CHTR2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1187336-C | New imidazole derivatives | ORION CORP (FI) | 2005-02-02 | — | — | CN | disclosed |
| EP-1261588-B1 | IMIDAZOLE COMPOUNDS AS Alpha2-ADRENOCEPTORS ANTAGONISTS | ORION CORP (FI) | 2004-10-20 | — | — | EP | disclosed |
| CN-1395567-A | New imidazole derivatives | ORION CORP (FI) | 2003-02-05 | — | — | CN | disclosed |
| WO-2001051472-A9 | NEW IMIDAZOLE DERIVATIVES | ORION CORP (FI) | 2003-01-23 | — | — | WO | disclosed |
| EP-1261588-A1 | NEW IMIDAZOLE DERIVATIVES | ORION CORPORATION (FI) | 2002-12-04 | — | — | EP | disclosed |
| US-6388090-B2 | IMIDAZOLE DERIVATIVES CONTAINING BICYCLIC AROMATIC OR AN HETEROCYCLIC RING FUSED WITH BENZENE EXHIBIT AFFINITY FOR ALPHA2 ADRENOCEPTORS SO TREATS THE DISEASE AFFECTED BY ALPHA2 ADRENOCEPTORS, E.G. NUROLOGICAL, PSYCHIATRIC OR COGNITION | ORION CORPORATION (FI) | 2002-05-14 | — | — | US | disclosed |
| US-20010056109-A1 | Imidazole derivatives | ORION CORPORATION (FI) | 2001-12-27 | — | — | US | disclosed |
| WO-2001051472-A1 | NEW IMIDAZOLE DERIVATIVES | ORION CORPORATION (FI) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056109-A1 | Imidazole derivatives | ADRB2, ADRB1, ADRA1D | SIGMAR1 82/4885MEN1 1609/4885CYP3A4 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.